Pharmacodynamics of cannabinoids

The Main Therapeutic Applications of Cannabidiol (CBD) and Its Potential Effects on Aging with Respect to Alzheimer’s Disease

“…The endocannabinoidome exhibits functions of anti-inflammatory and anti-excitotoxic barriers [6] and can be positively modulated by the administration of either phytocannabinoids or other cannabinoid receptor agonistic ligands [7,8,10,[16][17][18][19][20][21][22][23][24] or even by interactions with enhancers of the endocannabinoid activities without binding to cannabinoid receptors, e.g., endocannabinoid biodegradation inhibitors [11,[25][26][27][28].…”

“…In the treatment of health problems in the elderly, therapy with cannabinoids [21,34,35] or indirect modulators of endocannabinoid mechanisms [26,27] is increasingly recommended for many indications.…”

“…It activates the adenosine receptors A1, GABAergic GABAA receptors, and the nuclear receptor PPARγ. CBD is an inverse agonist for the G-protein-coupled receptors 3, 6, and 12 (GPR3, GPR6, and GPR12) [21,52]. Furthermore, it stimulates α1 and α1β subunits of the glycine receptors and has a partially agonistic effect on dopamine D2 receptors.…”

“…Furthermore, it stimulates α1 and α1β subunits of the glycine receptors and has a partially agonistic effect on dopamine D2 receptors. It has agonistic activity on the ionotropic receptors TPPA1, TRPV1, TRPV2, TRPV3, TRPV4, and TRPV8 [21,51]. It has been found that CBD also binds to the μ-opioid receptor (MOR) and the δ-opioid receptor (DOR) [53].…”